COVID-19 vaccine immunogenicity in Australian patients with multiple sclerosis

Study Aim Description

To determine vaccine-induced SARS-CoV2 Spike antibody in a cohort of MS patients treated withhigh and medium efficacy immunotherapy and compare that to those treated with interferon and glatiramer acetate treated patients.

Study Eligibility/Requirements

Participants must be over 18, diagnosed with MS and able to give consent. Particpants must also be receiving high and medium efficacy immunotherapy and intending to receive a COVID-19 vaccine.